Establishment Labs (NASDAQ:ESTA) Sets New 52-Week High – Time to Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s share price reached a new 52-week high on Thursday . The stock traded as high as $86.00 and last traded at $85.2260, with a volume of 59029 shares trading hands. The stock had previously closed at $82.39.

Wall Street Analyst Weigh In

ESTA has been the subject of a number of research reports. Mizuho lifted their target price on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. BTIG Research upped their price target on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Needham & Company LLC increased their price objective on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, TD Cowen restated a “buy” rating on shares of Establishment Labs in a research note on Monday, June 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.14.

Establishment Labs Price Performance

The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The company has a market capitalization of $2.50 billion, a P/E ratio of -56.92 and a beta of 1.11. The company’s 50-day simple moving average is $71.23 and its 200 day simple moving average is $69.70.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $57.40 million. During the same quarter in the prior year, the business posted ($0.70) EPS. The firm’s revenue for the quarter was up 44.7% compared to the same quarter last year. As a group, sell-side analysts expect that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares of the company’s stock, valued at $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 330,000 shares of company stock worth $22,854,538 in the last 90 days. 9.99% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. KBC Group NV acquired a new stake in Establishment Labs in the 1st quarter worth approximately $28,000. Quarry LP bought a new position in shares of Establishment Labs in the third quarter valued at approximately $34,000. Kestra Advisory Services LLC acquired a new stake in shares of Establishment Labs in the fourth quarter worth $47,000. Osaic Holdings Inc. boosted its holdings in shares of Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the period. Finally, MV Capital Management Inc. acquired a new position in Establishment Labs in the 4th quarter valued at $146,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.